The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models

Parasites and Vectors

Volumn 9, Issue 1, 2016, Pages

  Halliday, Alice ^a   Turner, Joseph D ^a   Guimarães, Ana ^a   Bates, Paul A ^b   Taylor, Mark J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Adjuvant; Leishmania; Lipopeptide; Lymphatic filariasis; Toll like receptor; Vaccine

Indexed keywords

HELMINTH VACCINE; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEISHMANIA VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG; VACCINE; LIPOPEPTIDE; PAM(3)CSK(4) PEPTIDE; PAM2CSK4 LIPOPEPTIDE; PROTOZOAL VACCINE; TLR11 PROTEIN, MOUSE; TLR12 PROTEIN, MOUSE; TLR6 PROTEIN, MOUSE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BRUGIA MALAYI; BRUGIAN FILARIASIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMORAL IMMUNITY; INFECTION PREVENTION; LEISHMANIA MAJOR; LEISHMANIASIS; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PHENOTYPE; SPLEEN CELL; TH2 CELL; ADAPTIVE IMMUNITY; AGONISTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FILARIASIS; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRUGIA MALAYI; DISEASE MODELS, ANIMAL; FILARIASIS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LEISHMANIA MAJOR; LEISHMANIASIS; LIPOPEPTIDES; MICE; PROTOZOAN VACCINES; TH2 CELLS; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS;

EID: 84958260309     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-016-1381-0     Document Type: Article

References (58)

1. Duthie MS et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239(1):178-96.
2. Didierlaurent AM et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. J Immunol. 2009;183(10):6186-97.
3. Maisonneuve C et al. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111(34):12294-9.
4. Raman VS, et al. Adjuvants for Leishmania vaccines: From Models to Clinical Application. Front Immunol. 2012;3:144:1-15.
5. Llanos-Cuentas A et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010;28(46):7427-35.
6. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines. 2003;2(2):239-52.
7. Rhee EG et al. Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4 + and CD8 + T Cell Responses and Protection Against Leishmania major Infection. J Exp Med. 2002;195(12):1565-73.
8. Peters NC et al. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice. J Immunol. 2012;189(10):4832-41.
9. Becker I et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. 2003;130(2):65-74.
10. Kavoosi G, Ardestani SK, Kariminia A. The involvement of TLR2 in cytokine and reactive oxygen species (ROS) production by PBMCs in response to Leishmania major phosphoglycans (PGs). Parasitology. 2009;136(10):1193-9.
11. Vargas-Inchaustegui DA et al. Distinct Roles for MyD88 and Toll-Like Receptor 2 during Leishmania braziliensis Infection in Mice. Infect Immun. 2009;77(7):2948-56.
12. Walker PS et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999;96(12):6970-5.
13. Hernández MX et al. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunol Lett. 2006;105(1):38-47.
14. Peters NC, et al. Evaluation of Recombinant Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion Vaccines against Sand Fly-Transmitted Leishmania major in C57BL/6 Mice. J Immunol. 2012;189(10):4832-41.
15. Okwor I, Kuriakose S, Uzonna J. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge. Vaccine. 2010;28(33):5451-7.
16. Turner JD et al. A Randomized, Double-Blind Clinical Trial of a 3-Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection. Clin Infect Dis. 2006;42(8):1081-9.
17. Turner JD et al. Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis. J Biol Chem. 2009;284(33):22364-78.
18. Babayan SA, Allen JE, Taylor DW. Future prospects and challenges of vaccines against filariasis. Parasite Immunol. 2012;34(5):243-53.
19. Babayan SA et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol. 2006;36(8):903-14.
20. Rajan TV et al. Brugian infections in the peritoneal cavities of laboratory mice: kinetics of infection and cellular responses. Exp Parasitol. 2002;100(4):235-47.
21. Paciorkowski N, Shultz LD, Rajan TV. Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice. Infect Immun. 2003;71(3):1370-8.
22. Martin C et al. IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. Med Microbiol Immunol. 2000;189(2):67-74.
23. Benmohamed L et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol. 1997;27(5):1242-53.
24. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect Dis. 2002;2(7):425-31.
25. Jackson DC et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;101(43):15440-5.
26. Bancroft AJ et al. The role of CD4 cells in protective immunity to Brugia pahangi. Parasite Immunol. 1994;16(7):385-7.
27. Bates PA. Characterization of developmentally-regulated nucleases in promastigotes and amastigotes of Leishmania mexicana. FEMS Microbiol Lett. 1993;107(1):53-8.
28. Griffiths KG et al. Using an intravenous catheter to carry out abdominal lavage in the gerbil. Lab Anim (NY). 2010;39(5):143-8.
29. Bahar K et al. Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996;14(5):489-95.
30. Turner JD et al. Wolbachia Endosymbiotic Bacteria of Brugia malayi Mediate Macrophage Tolerance to TLR- and CD40-Specific Stimuli in a MyD88/TLR2-Dependent Manner. J Immunol. 2006;177(2):1240-9.
31. Finkelman FD et al. Lymphokine Control of in vivo Immunoglobulin Isotype Selection. Annu Rev Immunol. 1990;8(1):303-33.
32. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15(5):506-16.
33. Zaman M, Toth I. Immunostimulation by synthetic lipopeptide based vaccine candidates: structureactivity relationships. Front Immunol 2013;4:318:1-12.
34. Chua BY et al. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol Cell Biol. 2014;92(4):377-83.
35. Cote-Sierra J et al. Bacterial Lipoprotein-Based Vaccines Induce Tumor Necrosis Factor-Dependent Type 1 Protective Immunity against Leishmania major. Infect Immun. 2002;70(1):240-8.
36. Miles SA et al. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med. 2005;201(5):747-54.
37. Kima PE et al. Internalization of Leishmania mexicana Complex Amastigotes via the Fc Receptor Is Required to Sustain Infection in Murine Cutaneous Leishmaniasis. J Exp Med. 2000;191(6):1063-8.
38. Thomas BN, Buxbaum LU. Fc{gamma}RIII Mediates Immunoglobulin G-Induced Interleukin-10 and Is Required for Chronic Leishmania mexicana Lesions. Infect Immun. 2008;76(2):623-31.
39. Buxbaum LU, Scott P. Interleukin 10- and Fcγ Receptor-Deficient Mice Resolve Leishmania mexicana Lesions. Infect Immun. 2005;73(4):2101-8.
40. Yamazaki S et al. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One. 2011;6(4):e18833.
41. Zeng W et al. Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines. J Immunol. 2002;169(9):4905-12.
42. Hutchison S et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012;26(3):1272-9.
43. Gavin AL et al. Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling. Science. 2006;314(5807):1936-8.
44. Buwitt-Beckmann U et al. TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides. J Biol Chem. 2006;281(14):9049-57.
45. Eisenbarth SC et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122-6.
46. Coffman RL, Sher A, Seder RA. Vaccine Adjuvants: Putting Innate Immunity to Work. Immunity. 2010;33(4):492-503.
47. McKee AS, Munks MW, Marrack P. How Do Adjuvants Work? Important Considerations for New Generation Adjuvants. Immunity. 2007;27(5):687-90.
48. Flach TL et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17(4):479-87.
49. Gray CA, Lawrence RA. A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. Eur J Immunol. 2002;32(4):1114-20.
50. Martin C et al. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun. 2001;69(11):7067-73.
51. Sharmila S et al. Bacterial lipid modification enhances immunoprophylaxis of filarial abundant larval transcript-2 protein in Mastomys model. Parasite Immunol. 2013;35(7-8):201-13.
52. Dillon S et al. A Toll-Like Receptor 2 Ligand Stimulates Th2 Responses In Vivo, via Induction of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase and c-Fos in Dendritic Cells. J Immunol. 2004;172(8):4733-43.
53. Dillon S et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest. 2006;116(4):916-28.
54. Gowthaman U et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T-cell response. J Infect Dis. 2011;204(9):1328-38.
55. Pandey SP et al. Pegylated Bisacycloxypropylcysteine, a Diacylated Lipopeptide Ligand of TLR6, Plays a Host-Protective Role against Experimental Leishmania major Infection. J Immunol. 2014;193(7):3632-43.
56. Jayakumar A et al. TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia). PLoS Negl Trop Dis. 2011;5(6):e1204.
57. Awate S, Babiuk LA, and Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114:1-10.
58. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509-17.